Sinopharm Group Co. Ltd.
Sinopharm Group Co. Ltd.
Your view on SHTDY
Overview
What the company does, where it operates, and who runs it.
About Sinopharm Group Co. Ltd.
- Industry
- Medical - Distribution
- Sector
- Healthcare
- CEO
- Wanyong Lian
- Headquarters
- Sinopharm Group Building, Shanghai, CN
- Industry
- Medical - Distribution
- Sector
- Healthcare
- CEO
- Wanyong Lian
- Headquarters
- Sinopharm Group Building, Shanghai, CN
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business.
The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail drug stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers.
The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. As of December 31, 2021, this segment had 10,259 retail pharmacies. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies.
The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consultation, market information consultation and investigation, and convention and exhibition services.
In addition, it manages medical project investment, consulting, and technology training activities. Sinopharm Group Co. Ltd. has a strategic partnership with I-Mab to enhance its commercial capabilities and commercialization transformation.
The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. is a subsidiary of Sinopharm Industrial Investment Co., Ltd.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Sinopharm Group Co. Ltd., and the rating behind it. SHTDY last traded at $14.06, 5.8× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Sinopharm Group Co. Ltd.. Starting points for Sinopharm Group Co. Ltd.: P/E 5.8, EPS $11.29, beta 0.63 — an Medical - Distribution name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Sinopharm Group Co. Ltd.. Sinopharm Group Co. Ltd. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Sinopharm Group Co. Ltd.. Trailing twelve-month EPS for Sinopharm Group Co. Ltd. stands at $11.29. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Sinopharm Group Co. Ltd.. Sinopharm Group Co. Ltd. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Sinopharm Group Co. Ltd. valued side by side against its closest peers. Sinopharm Group Co. Ltd. is measured against Medical - Distribution peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Sinopharm Group Co. Ltd., and how their positions are changing. At a $8.77B market value, institutional positions materially move Sinopharm Group Co. Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Sinopharm Group Co. Ltd. executives and directors. Shares of Sinopharm Group Co. Ltd. have traded between $10.72 and $14.87 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Sinopharm Group Co. Ltd.. Sinopharm Group Co. Ltd. is a $8.77B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Sinopharm Group Co. Ltd.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Sinopharm Group Co. Ltd.. Coverage tracks Sinopharm Group Co. Ltd. within Medical - Distribution (Healthcare). Press releases and market coverage, newest first.